ImmunoGen, Inc. Reports on Additions to Its Industry-Leading ADC Technology Portfolio at ImmunoGen, Inc.-National Cancer Institute-EORTC Conference

Published: Oct 23, 2013

biotech jobs post your resume Help employers find you! Check out all the jobs and post your resume.

ImmunoGen, Inc. (Nasdaq: IMGN) today reported on additions to the Company’s portfolio of antibody-drug conjugate (ADC) technologies at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics meeting being held in Boston, MA.1,2,3 Of particular interest were presentations on the Company’s new platform of DNA-acting payload agents ImmunoGen has created to further extend the opportunity for ADC cancer treatments.

Help employers find you! Check out all the jobs and post your resume.

Back to news